APA (7th ed.) Citation

M, S. F., M, R. L., M, C. R., S, C., P, G., LF, S., . . . N, M. (2024). Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. Targeted oncology, 19(4), 565. https://doi.org/10.1007/s11523-024-01062-z

Chicago Style (17th ed.) Citation

M, Salgado Fernández, et al. "Rechallenge with Anti-EGFR Treatment in RAS/BRAF Wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group." Targeted Oncology 19, no. 4 (2024): 565. https://doi.org/10.1007/s11523-024-01062-z.

MLA (9th ed.) Citation

M, Salgado Fernández, et al. "Rechallenge with Anti-EGFR Treatment in RAS/BRAF Wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group." Targeted Oncology, vol. 19, no. 4, 2024, p. 565, https://doi.org/10.1007/s11523-024-01062-z.